Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised ESSVP IV funds in connection with its acquisition of Bergkvist-Insjön Aktiebolag
Mandate

Vinge has advised ESSVP IV funds in connection with its acquisition of Bergkvist-Insjön Aktiebolag

July 22, 2019 M&A

Vinge has advised ESSVP IV funds (advised by Orlando Nordics AB) and its portfolio company Dilasso Timber AB (publ) in connection with its acquisition of the sawmill company Bergkvist-Insjön Aktiebolag as well as Dilasso Timber’s issuance of a MSEK 750 million senior secured bond under a framework of SEK 1,150 million. 

Vinge’s team consisted of, among others, Kristina Ekberg and Hannah Kajlinger (M&A) and Fabian Ekeblad and Sofia Törnroth Nyberg (Banking and Finance).
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026